会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • miRNA를 타겟으로 한 신경퇴행성 질환 치료
    • 通过瞄准MIRNA治疗神经损伤性疾病
    • KR1020120088009A
    • 2012-08-08
    • KR1020100089651
    • 2010-09-13
    • 서울대학교산학협력단
    • 노재규이상건김만호주건정근화이순태
    • A61K38/16A61K31/7105A61K31/711A61P25/28
    • A61K31/7088A61K31/7105A61K31/711C12Q1/6883C12Q2600/158C12Q2600/178
    • PURPOSE: A pharmaceutical composition targeting specific miNRA for preventing or treating neurodegenerative diseases is provided to enhance BDNF and IGF-1 level and to enhance synapse regeneration. CONSTITUTION: A pharmaceutical composition for preventing and treating neurodegenerative diseases contains: pharmaceutically effective amount of antisense oligonucleotides having a sequence which is complementary to 2-7th nucleotide sequence; and a pharmaceutically acceptable carrier. The antisense oligonucleotide is a DNA or RNA molecule. A kit for diagnosing Alzheimer's disease contains a nuelcotide sequence of miR-424*, miR-18b*, miR-135a*, miR-1228, miR-320, miR-296-5p, miR-557, miR-338-5p, miR-206, miR-92a, miR-1238, miR-513a-5p, miR-423-5p, miR-188-5p, miR-140-3p, miR-575, miR-640, miR-1237, miR-191* or miR-134, complementary sequence or sequence thereof.
    • 目的:提供靶向特异性miNRA以预防或治疗神经变性疾病的药物组合物,以增强BDNF和IGF-1水平并增强突触再生。 构成:用于预防和治疗神经变性疾病的药物组合物含有:药学有效量的具有与第2-7个核苷酸序列互补的序列的反义寡核苷酸; 和药学上可接受的载体。 反义寡核苷酸是DNA或RNA分子。 用于诊断阿尔茨海默病的试剂盒含有miR-424 *,miR-18b *,miR-135a *,miR-1228,miR-320,miR-296-5p,miR-557,miR-338-5p, miR-206,miR-92a,miR-1238,miR-513a-5p,miR-423-5p,miR-188-5p,miR-140-3p,miR-575,miR-640, 191 *或miR-134,其互补序列或序列。